Susquehanna International Group
TVTX icon

Susquehanna International Group’s Travere Therapeutics TVTX Stock Holding History

Susquehanna International Group’s Portfolio TVTX Stock Details TVTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$11.2M Buy
376,700
+264,200
+235% +$7.9M ﹤0.01% 2941
2025
Q4 		$4.3M Buy
112,500
+22,000
+24% +$715K ﹤0.01% 4261
2025
Q3 		$2.16M Sell
90,500
-150,800
-62% -$2.84M ﹤0.01% 5604
2025
Q2 		$3.57M Buy
241,300
+211,100
+699% +$3.5M ﹤0.01% 4624
2025
Q1 		$541K Sell
30,200
-41,500
-58% -$842K ﹤0.01% 8730
2024
Q4 		$1.25M Sell
71,700
-69,600
-49% -$1.23M ﹤0.01% 6428
2024
Q3 		$1.98M Buy
141,300
+64,000
+83% +$667K ﹤0.01% 5289
2024
Q2 		$635K Buy
77,300
+28,600
+59% +$193K ﹤0.01% 7691
2024
Q1 		$375K Buy
48,700
+12,800
+36% +$108K ﹤0.01% 9173
2023
Q4 		$323K Sell
35,900
-20,400
-36% -$149K ﹤0.01% 9675
2023
Q3 		$503K Sell
56,300
-92,800
-62% -$1.31M ﹤0.01% 8206
2023
Q2 		$2.29M Sell
149,100
-56,900
-28% -$1.04M ﹤0.01% 4878
2023
Q1 		$4.63M Buy
206,000
+180,200
+698% +$3.83M ﹤0.01% 3568
2022
Q4 		$543K Buy
25,800
+3,400
+15% +$72K ﹤0.01% 7638
2022
Q3 		$552K Buy
22,400
+10,800
+93% +$279K ﹤0.01% 8223
2022
Q2 		$281K Sell
11,600
-18,200
-61% -$458K ﹤0.01% 9743
2022
Q1 		$768K Sell
29,800
-21,300
-42% -$566K ﹤0.01% 7826
2021
Q4 		$1.59M Sell
51,100
-57,100
-53% -$1.61M ﹤0.01% 6078
2021
Q3 		$2.62M Buy
108,200
+93,600
+641% +$1.72M ﹤0.01% 5247
2021
Q2 		$213K Sell
14,600
-6,200
-30% -$122K ﹤0.01% 11469
2021
Q1 		$519K Sell
20,800
-33,000
-61% -$912K ﹤0.01% 9372
2020
Q4 		$1.47M Sell
53,800
-13,400
-20% -$313K ﹤0.01% 5791
2020
Q3 		$1.24M Buy
67,200
+1,500
+2% +$29.2K ﹤0.01% 5605
2020
Q2 		$1.34M Buy
65,700
+9,200
+16% +$146K ﹤0.01% 5264
2020
Q1 		$824K Buy
56,500
+25,100
+80% +$378K ﹤0.01% 5823
2019
Q4 		$446K Sell
31,400
-32,000
-50% -$409K ﹤0.01% 7214
2019
Q3 		$735K Sell
63,400
-221,700
-78% -$3.66M ﹤0.01% 6394
2019
Q2 		$5.73M Buy
285,100
+164,300
+136% +$3.24M ﹤0.01% 2537
2019
Q1 		$2.73M Sell
120,800
-9,700
-7% -$214K ﹤0.01% 3276
2018
Q4 		$2.95M Buy
130,500
+22,700
+21% +$565K ﹤0.01% 2962
2018
Q3 		$3.1M Buy
+107,800
New +$3.08M ﹤0.01% 3321
2018
Q2 		– Sell
-14,800
Closed -$331K – 10449
2018
Q1 		$331K Buy
14,800
+1,700
+13% +$40.5K ﹤0.01% 7457
2017
Q4 		$276K Sell
13,100
-1,900
-13% -$43.4K ﹤0.01% 7729
2017
Q3 		$373K Buy
15,000
+4,200
+39% +$92.5K ﹤0.01% 7036
2017
Q2 		$209K Buy
+10,800
New +$196K ﹤0.01% 8218
2017
Q1 		– Sell
-80,100
Closed -$1.52M – 9975
2016
Q4 		$1.52M Buy
80,100
+3,500
+5% +$71.6K ﹤0.01% 4643
2016
Q3 		$1.71M Sell
76,600
-90,300
-54% -$1.72M ﹤0.01% 3817
2016
Q2 		$2.97M Buy
166,900
+34,600
+26% +$560K ﹤0.01% 2948
2016
Q1 		$1.81M Buy
132,300
+46,300
+54% +$702K ﹤0.01% 3975
2015
Q4 		$1.66M Buy
86,000
+26,400
+44% +$527K ﹤0.01% 4413
2015
Q3 		$1.21M Buy
59,600
+40,200
+207% +$1.19M ﹤0.01% 5298
2015
Q2 		$643K Sell
19,400
-421,300
-96% -$11.5M ﹤0.01% 7121
2015
Q1 		$10.6M Buy
+440,700
New +$6.72M ﹤0.01% 1823

Other funds holding TVTX

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
NAMI
Nomura Asset Management International Philadelphia, Pennsylvania $58.4B AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Susquehanna International Group's TVTX Position: Q1 2026 in Review

Susquehanna International Group reduced its Travere Therapeutics (TVTX) stake by 38% in Q1 2026, selling an estimated $745K and leaving 40,058 shares worth $1.19M. The position accounts for ﹤0.01% of the portfolio, ranked #7437.

Susquehanna International Group first reported a position in TVTX in Q4 2014 and has held it in 28 quarters since. The position peaked at $2.9M in Q1 2023. 260 funds tracked by Wall St. Rank hold TVTX as of Q1 2026.

  • Susquehanna International Group held 40,058 shares of Travere Therapeutics worth $1.19M as of Q1 2026.
  • Susquehanna International Group sold 24,914 Travere Therapeutics shares in Q1 2026, an estimated $745K.
  • Travere Therapeutics made up ﹤0.01% of Susquehanna International Group's portfolio in Q1 2026, its #7437 holding.
  • Susquehanna International Group first reported a position in Travere Therapeutics in Q4 2014 and has held it in 28 quarters since.
  • Susquehanna International Group's Travere Therapeutics position peaked at $2.9M in Q1 2023.
  • 260 funds tracked by Wall St. Rank held Travere Therapeutics as of Q1 2026.

Based on Susquehanna International Group's 13F filing for Q1 2026, filed 15 May 2026.